Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.
Second operation between the EIB and Mobidiag after first loan in 2016.
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of infectious diseases and antimicrobial resistance, has signed a EUR 25 million growth capital loan with the European Investment Bank (EIB). The EIB loan will be supported by the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe, through the European Growth Finance Facility (EGFF) initiative. This new four-year loan will allow Mobidiag to advance its research and development and facilitate further validation and commercialisation of molecular diagnostics tests on the Company’s Amplidiag® and Novodiag® platforms.
Tuomas Tenkanen, CEO of Mobidiag, said: "This EIB loan is a further validation of Mobidiag’s progress as we become a leading player in the molecular diagnostics market providing innovative and differentiated solutions that are adopted by key laboratories throughout Europe. Following extensive R&D and clinical validation, we are proud that our state-of-the-art technology is now commercially available internationally. This loan will allow us to accelerate the development of the Mobidiag platform content to the next level, and build significant value over the coming years by building a comprehensive portfolio of diagnostics tests that can be used on our devices. We are delighted to have the EIB’s support and look forward to working with them again.”
At the signature, EIB Vice-PresidentAlexander Stubb, remarked: “Boosting the innovation capacity of a European life science business and helping to preserve relevant sectoral know-how in Europe is of major importance right now. The EIB used to be known as an infrastructure bank, but in recent years it has made an important shift towards supporting innovative companies, and very noticeably so in Finland. Our support has helped Mobidiag to continue its growth, and we’re glad to renew our commitment to this great company.”
European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, added: “Researching and developing ways to stop the spread of infectious diseases is hugely important work but it comes at a high cost. With the support of the EFSI guarantee, the EIB can lend Mobidiag the financing it needs to realise its ambitions and make the world a safer and healthier place to live.”
Since 2016, the EIB has contributed significantly to the growth of Mobidiag through the provision of a EUR 15 million loan facility, the final tranche of which was obtained in November 2018. The loan enabled Mobidiag to successfully achieve a number of operational milestones in the development, validation and subsequent launch of the innovative and proprietary ‘sample-in, result-out’ diagnostic solution Novodiag®. With this new EUR 25 million loan, Mobidiag will continue to seek growth through the extension of its product pipeline
Europe’s 15 best social innovators will compete at the grand finale of the 12th European Investment Bank Institute Social Innovation Tournament, which will be held in Stockholm on 28 September under the auspices of EIB Vice-President Thomas Östros.
The European Investment Bank (EIB) has signed a €315 million finance contract with Cellnex to support the development of the mobile telecoms infrastructure behind 5G rollouts in Spain, Portugal, France, Italy and Poland. The loan will mobilise total investment of €631 million to improve and expand the coverage and capacity of very high bandwidth mobile network infrastructure in these countries, helping to speed up the digital transition in both urban and rural areas.
The European Investment Bank (EIB) and the Republic of Lithuania have signed a €300 million financing agreement to support investment in long-term competitiveness, job creation and the green and digital transitions in the 2021-2027 period.